(firstQuint)Dasotraline Pediatric ADHD Study.

 This is a randomized, double blind, multicenter, placebo-controlled, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in subjects 6 to 12 years of age with ADHD using 2 doses of dasotraline (2 mg/day and 4 mg/day) versus placebo over a 6 week treatment period.

 The study will consist of screening, treatment, and end of study visits.

.

 Dasotraline Pediatric ADHD Study@highlight

This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.

